Brokerages Set ICU Medical, Inc. (NASDAQ:ICUI) PT at $179.33

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have earned an average recommendation of “Moderate Buy” from the five research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $179.3333.

ICUI has been the subject of a number of recent research reports. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, February 15th. KeyCorp boosted their price target on shares of ICU Medical from $175.00 to $180.00 and gave the company an “overweight” rating in a report on Friday, February 20th. Piper Sandler upped their price target on shares of ICU Medical from $172.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC raised its holdings in shares of ICU Medical by 2.5% during the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock valued at $1,297,000 after buying an additional 229 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in ICU Medical by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after buying an additional 560 shares in the last quarter. United Services Automobile Association acquired a new stake in ICU Medical in the 1st quarter valued at approximately $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in ICU Medical by 32.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock valued at $9,472,000 after acquiring an additional 16,680 shares during the period. Finally, Intech Investment Management LLC raised its stake in ICU Medical by 38.6% during the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock valued at $1,658,000 after acquiring an additional 3,326 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $125.22 on Friday. The company has a market cap of $3.13 billion, a PE ratio of 6,264.13, a P/E/G ratio of 1.86 and a beta of 0.85. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $160.29. The firm has a 50-day simple moving average of $141.65 and a 200 day simple moving average of $137.94. The company has a quick ratio of 1.15, a current ratio of 2.39 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.68 by $0.23. The firm had revenue of $535.94 million for the quarter, compared to analysts’ expectations of $541.20 million. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. ICU Medical’s revenue was down 14.1% on a year-over-year basis. During the same quarter last year, the company posted $2.11 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, sell-side analysts anticipate that ICU Medical will post 4.11 EPS for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.